BlossomHill Therapeutics Announces Alignment With FDA On 50mg Twice Daily As Recommended Phase 2 Dose For BH-30643
Benzinga Newsdesk 9 hours ago
FDANews
SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027
SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027